Skip to main content

Table 1 The registered institutions

From: Concept and design of a nationwide prospective feasibility/efficacy/safety study of weekly paclitaxel for patients with pathologically confirmed anaplastic thyroid cancer (ATCCJ-PTX-P2)

Institution

1. Osaka City University Hospital, Osaka

2. Kuma Hospital, Kobe

3. Kanaji Hospital, Tokyo

4. Ito Hospital, Tokyo

5. Shinshu University Hospital, Nagano

6. Cancer Institute Hospital, Tokyo

7. Nagasaki University Hospital, Nagasaki

8. Kanagawa Cancer Center, Kanagawa

9. Tsukuba University Hospital, Ibaraki

10. Fukushima Medical University Hospital, Fukushima

11. Nagasaki Medical Center Hospital, Nagasaki

12. Tohoku University Hospital, Sendai

13. Noguchi Hospital, Beppu

14. Aichi Cancer Center Hospital, Nagoya

15. International University of Health and Welfare, Mita Hospital, Tokyo

16. Ida Municipal Hospital, Nagano

17. Mito National Medical Center, Ibaraki

18. Sumitomo Hospital, Osaka

19. Tokyo Medical University Hachioji Medical Center, Tokyo

20. Narita Red Cross Hospital, Chiba

21. National Cancer Center Hospital, Tokyo

22. Uchimaru Hospital, Morioka

23. Iwate Medical University Hospital, Morioka

24. Yokohama City University Hospital, Kanagawa

25. Yokohama City University Medical Center, Kanagawa

26. Kanazawa University Hospital, Ishikawa

27. Nippon Medical School Hospital, Tokyo

28. Kanazawa Medical University Hospital, Ishikawa